Chemomab Therapeutics Ltd. — Company profile
Healthcare · Biotechnology · Israel
Last price 1.09 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 7.90M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.
Details
| Name | Chemomab Therapeutics Ltd. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 3 |
| Founded | 2004 |
| Ceo | Adi George |
| Country | Israel |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US16385C2035 |
| Cusip | 16385C203 |
| Cik | 1534248 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Dr. Adi Mor George Ph.D. | Co-Founder, Chief Scientific Officer, Chief Executive Officer and Executive Director |
| Sigal Fattal CPA, M.B.A. | Chief Financial Officer |
| John Lawler | Chief Development Officer |
| Barbara L. Lindheim | Consulting Vice President of Investor and Public Relations, Strategic Communications |
| Dr. David M. Weiner M.B.A., M.D. | Interim Chief Medical Officer |
Contact
| Address | Building C, 10th Floor, Tel Aviv-Yafo, 6158101, Israel |
| Phone | 972 77 331 0156 |
| Website | https://www.chemomab.com |